Assenagon Asset Management S.A. Apellis Pharmaceuticals, Inc. Transaction History

Assenagon Asset Management S.A.

$54.1 Billion
Q4 2024

A detailed history of Assenagon Asset Management S.A. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 29,993 shares of APLS stock, worth $911,487. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,993

Previous 2,144,415 98.6%

Holding current value

$911,487

Previous $61.8 Million 98.45%

% of portfolio

0.0%

Previous 0.13%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 14, 2025	SELL	$26.18 - $35.42 $55.4 Million - $74.9 Million	-2,114,422 Reduced 98.6%	29,993 $957,000
Q3 2024 Oct 23, 2024	BUY	$28.84 - $41.15 $40.7 Million - $58 Million	1,409,707 Added 191.87%	2,144,415 $61.8 Million
Q2 2024 Jul 18, 2024	SELL	$38.07 - $59.71 $49.1 Million - $77 Million	-1,288,906 Reduced 63.69%	734,708 $28.2 Million
Q1 2024 Apr 24, 2024	SELL	$55.39 - $72.47 $6.72 Million - $8.8 Million	-121,390 Reduced 5.66%	2,023,614 $119 Million
Q4 2023 Jan 17, 2024	BUY	$37.14 - $64.82 $41.7 Million - $72.7 Million	1,121,497 Added 109.57%	2,145,004 $128 Million
Q3 2023 Nov 06, 2023	BUY	$23.65 - $89.22 $12.4 Million - $46.8 Million	524,797 Added 105.23%	1,023,507 $38.9 Million
Q2 2023 Jul 25, 2023	SELL	$76.68 - $93.31 $18.8 Million - $22.8 Million	-244,536 Reduced 32.9%	498,710 $45.4 Million
Q1 2023 Apr 18, 2023	BUY	$46.59 - $66.96 $722,937 - $1.04 Million	15,517 Added 2.13%	743,246 $49 Million
Q4 2022 Jan 12, 2023	SELL	$43.24 - $61.04 $21.5 Million - $30.4 Million	-497,607 Reduced 40.61%	727,729 $37.6 Million
Q3 2022 Oct 27, 2022	BUY	$44.76 - $69.66 $15.3 Million - $23.8 Million	341,898 Added 38.7%	1,225,336 $83.7 Million
Q2 2022 Jul 27, 2022	BUY	$35.07 - $59.21 $13 Million - $21.9 Million	370,411 Added 72.2%	883,438 $39.9 Million
Q1 2022 Apr 25, 2022	BUY	$35.46 - $54.12 $15.8 Million - $24.1 Million	445,745 Added 662.5%	513,027 $26.1 Million
Q4 2021 Feb 01, 2022	BUY	$30.74 - $49.16 $2.07 Million - $3.31 Million	67,282 New	67,282 $3.18 Million
Q3 2021 Oct 19, 2021	SELL	$31.4 - $69.84 $7.4 Million - $16.5 Million	-235,775 Closed	0 $0
Q2 2021 Jul 15, 2021	BUY	$40.9 - $64.9 $9.64 Million - $15.3 Million	235,775 New	235,775 $14.9 Million
Q4 2020 Feb 01, 2021	SELL	$30.79 - $57.2 $505,972 - $939,967	-16,433 Closed	0 $0
Q3 2020 Oct 07, 2020	BUY	$25.89 - $33.65 $425,450 - $552,970	16,433 New	16,433 $496,000
Q4 2019 Jan 17, 2020	SELL	$22.1 - $30.8 $537,295 - $748,809	-24,312 Closed	0 $0
Q3 2019 Oct 16, 2019	BUY	$24.09 - $32.18 $585,676 - $782,360	24,312 New	24,312 $586,000
Q2 2019 Aug 12, 2019	SELL	$18.0 - $25.34 $5.56 Million - $7.83 Million	-308,992 Closed	0 $0
Q1 2019 Apr 26, 2019	BUY	$12.81 - $19.82 $3.96 Million - $6.12 Million	308,992 New	308,992 $6.03 Million

Others Institutions Holding APLS

# of Institutions

310

Shares Held

113M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.34B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.

Account

Assenagon Asset Management S.A. Apellis Pharmaceuticals, Inc. Transaction History